
    
      Eligible patients will undergo comprehensive evaluation. Informants familiar with the patient
      will also provide information. Patients will be randomized to receive treatment or placebo.
      During the 12-week treatment there will be weekly monitoring for the first 4 weeks and
      biweekly monitoring for the next 8 weeks. The drug dosage will be increased each week as
      tolerated by the patient. Serum levels of fluoxetine and norfluoxetine will be documented at
      Week 12.

      Completion date provided represents the completion date of the grant per OOPD records
    
  